Clinical Trials · NCT00398489
Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- Technical University of Munich
- Enrollment
- 94
- Start date
- Oct 2006
- Locations
- 5 sites, Germany
- Primary endpoint
- Rate of pathologic complete remission (pCR) after neoadjuvant therapy comprising docetaxel and trastuzumab (Herceptin®) in women with locally advanced, HER2-positive, operable breast cancer